Several other research analysts have also recently issued reports on ECYT. Zacks Investment Research raised Endocyte from a sell rating to a hold rating in a research note on Thursday, November 9th. ValuEngine cut Endocyte from a hold rating to a sell rating in a research note on Tuesday, November 14th.
Endocyte (ECYT) opened at $4.20 on Tuesday. Endocyte has a 52 week low of $1.17 and a 52 week high of $6.55.
In other Endocyte news, VP Christopher P. Leamon sold 23,231 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $5.04, for a total transaction of $117,084.24. Following the sale, the vice president now owns 150,579 shares of the company’s stock, valued at approximately $758,918.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Philip S. Low sold 50,511 shares of the stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $4.41, for a total value of $222,753.51. Following the sale, the insider now directly owns 354,050 shares in the company, valued at approximately $1,561,360.50. The disclosure for this sale can be found here. Insiders have sold a total of 124,253 shares of company stock worth $562,591 in the last ninety days. Insiders own 14.86% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC boosted its position in Endocyte by 0.9% during the 2nd quarter. FMR LLC now owns 3,540,203 shares of the biopharmaceutical company’s stock valued at $5,310,000 after acquiring an additional 31,168 shares in the last quarter. Perceptive Advisors LLC bought a new stake in Endocyte during the 4th quarter valued at $6,213,000. BlackRock Inc. boosted its position in Endocyte by 223.7% during the 4th quarter. BlackRock Inc. now owns 1,138,791 shares of the biopharmaceutical company’s stock valued at $4,875,000 after acquiring an additional 786,933 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Endocyte by 1,064.3% during the 2nd quarter. Goldman Sachs Group Inc. now owns 430,994 shares of the biopharmaceutical company’s stock valued at $646,000 after acquiring an additional 393,975 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Endocyte by 42.0% during the 4th quarter. Renaissance Technologies LLC now owns 293,580 shares of the biopharmaceutical company’s stock valued at $1,257,000 after acquiring an additional 86,800 shares in the last quarter. 19.45% of the stock is currently owned by institutional investors and hedge funds.
Endocyte Inc (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company’s pipeline includes Folate-Tubulysin (EC1456), the Company’s second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company’s non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).
Receive News & Ratings for Endocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endocyte and related companies with MarketBeat.com's FREE daily email newsletter.